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Abstract: BACKGROUND The academia-industry interface is important, and, despite challenges that
inevitably occur, bears the potential for positive synergies to emerge. Perceived barriers to wider col-
laboration in academia-industry oncology research in Europe need to be addressed, current academic
cooperative group and industry models for collaboration need to be discussed, and a common termi-
nology to facilitate understanding of both sectors’ concerns needs to be established with an eye to-
wards improving academia-industry partnerships on clinical trials for the benefit of patients with cancer.
METHODOLOGY CAREFOR (Clinical Academic Cancer Research Forum), a multi-stakeholder plat-
form formed to improve the direction for academic clinical trials in the field of oncology in Europe,
formed the CAREFOR-Industry Working Group comprised of experienced professionals from European
academic cooperative groups joined by industry representatives selected based on their activities in the
area of medical oncology. They jointly discussed academic cooperative groups, clinical trials conducted
between academic cooperative groups and industry, examples of successful collaborative models, common
legal negotiation points in clinical trial contracts, data access, and principles of interaction. RESULTS
Four principles of interaction between the academia and industry are proposed: (1) clarify the roles and
responsibilities of all partners involved in the study, (2) involve legal teams from an early stage; (3)
acknowledge that data is an important output of the study, (4) agree on the intent of the trial prior
to its start. CONCLUSIONS The CAREFOR-Industry Working Group describes current models, chal-
lenges, and effective strategies for academia-industry research in Europe with an eye towards improving
academia-industry partnerships on clinical trials for patients with cancer. Current perceived challenges
are explained, and future opportunities/recommendations for improvement are described for the areas
of most significant impact. Challenges are addressed from both the academic and industry perspectives,
and principles of interaction for the optimal alignment between academia and industry in selected areas
are proposed.
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Key questions
What is already known about this subject?
 ► The academia- industry interface is important, and, 
despite challenges that inevitably occur, bears the 
potential for greatly positive synergies to emerge.
 ► There are perceived barriers to wider collaboration 
in academia/industry oncology research in Europe.
 ► The types of clinical trials conducted between in-
dustry and academia include Industry Sponsored 
Clinical Trials and Investigator Initiated Trials.
What does this paper add?
 ► There is a need to examine, discuss and either clarify 
or improve on the way academia- industry research 
is being conducted.
 ► There are several drivers for change in academia- 
industry collaboration: collaboration and exchange 
of knowledge, streamlined contracting and agree-
ments, bidirectional exchange of knowledge and 
exchange of samples and technology.
 ► The value of the collaboration can be maximised by 
focussing on strengths and mutual areas of inter-
est, crafting a collaboration model and contract that 
is fit for the given purpose and focussing on pro-
grammes that provide meaningful scientific patient- 
centric advances that go beyond only competitive 
considerations.
How might this impact on clinical practice?
 ► Principles of interaction between academia and in-
dustry were developed, and these provide guidance 
towards creating a clear and successful collabora-
tion provided that the clinical trials performed cap-
ture data of sufficient quality. Patients with cancer 
are the ultimate beneficiaries.
ABSTRACT
Background The academia- industry interface is 
important, and, despite challenges that inevitably occur, 
bears the potential for positive synergies to emerge. 
Perceived barriers to wider collaboration in academia- 
industry oncology research in Europe need to be 
addressed, current academic cooperative group and 
industry models for collaboration need to be discussed, 
and a common terminology to facilitate understanding of 
both sectors’ concerns needs to be established with an 
eye towards improving academia- industry partnerships on 
clinical trials for the benefit of patients with cancer.
Methodology CAREFOR (Clinical Academic Cancer 
Research Forum), a multi- stakeholder platform formed 
to improve the direction for academic clinical trials in the 
field of oncology in Europe, formed the CAREFOR- Industry 
Working Group comprised of experienced professionals 
from European academic cooperative groups joined by 
industry representatives selected based on their activities 
in the area of medical oncology. They jointly discussed 
academic cooperative groups, clinical trials conducted 
between academic cooperative groups and industry, 
examples of successful collaborative models, common 
legal negotiation points in clinical trial contracts, data 
access, and principles of interaction.
Results Four principles of interaction between the 
academia and industry are proposed: (1) clarify the roles 
and responsibilities of all partners involved in the study, (2) 
involve legal teams from an early stage; (3) acknowledge 
that data is an important output of the study, (4) agree on 
the intent of the trial prior to its start.
Conclusions The CAREFOR- Industry Working Group 
describes current models, challenges, and effective 
strategies for academia- industry research in Europe 
with an eye towards improving academia- industry 
partnerships on clinical trials for patients with cancer. 
Current perceived challenges are explained, and future 
opportunities/recommendations for improvement are 
described for the areas of most significant impact. 
Challenges are addressed from both the academic and 
industry perspectives, and principles of interaction for 
the optimal alignment between academia and industry in 
selected areas are proposed.
INTRODUCTION
The academia- industry interface is impor-
tant, and, despite challenges that inevitably 
occur, bears the potential for greatly positive 
synergies to emerge.
CAREFOR (Clinical Academic Cancer 
Research Forum), a multi- stakeholder 
Open access
2 Stahel RA, et al. ESMO Open 2020;5:e000628. doi:10.1136/esmoopen-2019-000628
platform formed to improve the direction for academic 
clinical trials in the field of oncology in Europe,1 includes 
the European Society for Medical Oncology (ESMO), the 
European Organisation for Research and Treatment of 
Cancer (EORTC), the European Association for Cancer 
Research (EACR) and is joined by European and inter-
national cooperative groups, umbrella organisations, 
medical societies, national cooperative groups and cancer 
centres in an effort to institutionalise academic cancer 
clinical research in the European landscape and, notably, 
structure collaboration with industry. CAREFOR formed 
the CAREFOR- Industry Working Group which comprises 
experienced professionals from European academic 
cooperative groups joined by selected industry represen-
tatives. The industry representatives were selected based 
on their activities in the area of medical oncology and 
their presence at the ESMO Congresses. In this paper, the 
CAREFOR- Industry Working Group identifies:
1. General Categories of Academic Cooperative Groups 
in Europe;
2. Types of Clinical Trials Conducted between Academic 
Cooperative Groups and Industry;
3. Examples of Successful Collaborative Models for 
Academia- Industry Clinical Trials;
4. Current Challenges for Academia Clinical Trials in Eu-
rope;
5. Common Legal Negotiation Points in Contracts for 
Clinical Trials between Academic Cooperative Groups 
and Industry;
6. Data Access and Management Models to Govern the 
Flow of Information and Data between Academia and 
Industry;
7. Emerging Collaborative Models;
8. Principles of Interaction between Academia and 
Industry.
The article seeks to address perceived barriers to wider 
collaboration in academia/industry oncology research 
in Europe by discussing current academic cooperative 
group and industry models for collaboration and estab-
lishing a common terminology to facilitate understanding 
of both sectors’ concerns with an eye towards improving 
academia- industry partnerships on clinical trials for 
the benefit of patients with cancer. The challenges are 
addressed from both the academic and industry perspec-
tives, and best practices, the optimal alignment between 
academia and industry in selected areas, are proposed 
throughout the article.
For purposes of clarity, when we discuss academic part-
nerships with industry, we are not referring to academic 
partnerships between a large hospital and the pharma-
ceutical industry, but rather to partnerships between 
industry and large established European academic 
groups whose membership is voluntary and comprise 
tens to hundreds of hospitals and institutions, that is, 
collectives coming from either one or multiple coun-
tries in the case of national and international academic 
cooperative groups. In this light and concerning termi-
nology and definitions, the variety of academic groups 
are introduced based on their geographic membership, 
capabilities and expertise. Common definitions are 
provided for clinical trials conducted by academia and 
clinical trials conducted by industry. Snapshots of collab-
orative models are provided, all the while keeping in 
mind the expectations, capabilities and resources of the 
involved partners. With this approach, the CAREFOR- 
Industry Working Group aims to shine a light on the 
current issues and outline best practices that might serve 
to mitigate perceived challenges for academic research 
within Europe.
It is noted, that further discussion on these areas may 
be warranted with stakeholders outside of the CAREFOR- 
Industry Working Group in order for this effort to have 
the utmost impact on improving the current state of 
affairs.
GENERAL CATEGORIES OF ACADEMIC COOPERATIVE GROUPS IN 
EUROPE
The landscape of academic cooperative groups in 
Europe comprises different categories of groups occu-
pying specific niches in cancer clinical research. An over-
view of the categories and niches of academic groups 
is warranted, because the collaboration model with 
industry needs to fit with the resources and expertise of 
the respective category of academic group and the regu-
lations it must adhere to within its membership’s geog-
raphy. For purposes of this overview, we consider three 
general categories of academic cooperative groups (see 
table 1):
1. Small Academic Cooperative Groups;
2. Large Academic Cooperative Groups;
3. Umbrella Networks of Cooperative Groups.
Regulatory autonomy and expertise constitute major 
differences between large and small academic groups 
which impact the models of partnership and are also the 
criteria for academic independence. While small, large 
and umbrella academic cooperative groups participate 
in commercial regulatory trials with the pharmaceutical 
industry (if the capability or resource can be provided), it 
is recognised that the more an academic group enforces 
principles of regulatory autonomy and independence, 
the more the group requires in- house expertise in regula-
tory and legal issues.
It is important for industry to keep in mind the partic-
ular capabilities of each category of academic coop-
erative group, what each can offer, as well as what they 
require within a collaboration. Here we also note that 
from the perspective of academia, it sometimes appears 
that there is a misunderstanding in confusing academia 
with contract research organisations (CROs). There is a 
consequent need for industry to explore how to partner 
with academia and engage them as an equal partner. 
Academia also points out, that industry’s expectations for 
speed and rapidness need to conform to the purpose and 
the available resources.
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Table 1 General categories of academic cooperative groups








Expertise in a 
particular disease 
area.
Generally, they need to 
engage a contract research 
organisation.
Small size limits resources. 
Geographically located in one 
or two countries with common 
regulatory and legal requirements. 
Limited number of sites. Phase II 














a large network of 
investigators.
Possess in- house operational 
methodologies. Can transfer 
in- house data sets into 
regulatory dossiers. Pursue 
studies for secondary label 
indications at lower cost 
than industry sponsored 
clinical trials. Help with health 
technology assessment.11 
Reduce duplication of efforts 
by coordinating group 
activities.
Multidisciplinary, international, 
expertise enables conduct of 
complex studies, for example, 
using biomarker section. Phase II 









experts and multiple 
cooperative groups, 
both small and large 
groups from many 
countries and from a 
particular field.
Dependent on resources 
of members. Reduce 
duplication of efforts through 
standardising processes 
among many small and large 
academic cooperative groups.
Take advantage of combined, 
international, resources of member 
cooperative groups. Conduct trials 
in rare diseases and/or in specific 
subtypes or subpopulations of 
patients. Phase II or III studies. 
Large number of trial sites.
TYPES OF CLINICAL TRIALS CONDUCTED BETWEEN INDUSTRY 
AND ACADEMIA: INDUSTRY SPONSORED CLINICAL TRIALS 
VERSUS INVESTIGATOR INITIATED TRIALS
The priorities used by academic cooperative groups 
and industry to manage their portfolios of work overlap 
considerably. Both are driven by prospects of important 
scientific advances and considerations of public health, 
including the health of patients with orphan diseases. 
Industry, of course, has to meet these needs to benefit 
its owners (often pension funds), while academic coop-
erative groups must manage within their annual budget. 
They do not consider concepts such as return on invest-
ment or the issue of ‘sustainability’ of the business in 
choosing how to invest, but prioritise merely by scientific/
patient merit. This makes academic cooperative groups 
more willing to risk capital without a possibility of return, 
and hence they are more risk tolerant than industry when 
it comes to investing in novel ideas and science. However, 
from the industry perspective, it should be noted that 
industry makes a significant investment in science and 
novel ideas, especially in early research.
A general overview of the types of clinical trials 
conducted between industry and academia emphasising 
differences between industry sponsored clinical and 
investigator initiated trials (IITs) is provided in table 2.
A recent change in the clinical trial landscape is, that 
regulatory approval may no longer be the most chal-
lenging obstacle. One can develop hundreds of check-
point inhibitors, and several may receive European 
Medicines Agency (EMA) approval. The challenge has 
shifted to access based on health technology assessment, 
societal and patient- centred aspects. This is where part-
nerships should be developed, because academic groups 
may be well- suited to meet societal agendas more than 
pure regulatory trial activities, which are needed, but no 
longer sufficient to obtain the widest possible access to 
innovative therapies.
In the academic clinical trial model, the Phase I/Ib trial 
is seen as a trial designed to learn. However, many Phase 
I/Ib trials are conducted outside of academic cooperative 
groups, because not all academic sites have the capability 
or expertise to conduct Phase Ib trials. This is a legitimate 
concern for industry. Furthermore, industry is generally 
reluctant to give a molecule to a broad range of sites, 
because the oversight needed to manage early drug devel-
opment is generally handled by a selected number of sites 
with the experience to manage the unknown dosing and 
safety profile of a new medicine, which requires special-
ised operational capabilities and the ability to agree to 
standard contract terms to oversee drug development 
at this early stage of dose escalation and first in human 
trials. Here, industry would like to find additional ways to 
partner with academia in a cooperative group setting in 
order for the Phase Ib setting to work well.
Currently, industry often performs Phase I/Ib trials as 
pharma sponsored trials. However, to overcome this pref-
erence, cooperative groups would need to have a small 
network of sites that can provide the data and timelines 
needed for Phase I/Ib. It is worth noting, that industry 
does not necessarily want cooperative groups to shift 
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Table 2 Industry sponsored clinical trials versus investigator initiated trials
Industry- sponsored clinical trials Investigator initiated trials
Designed to evaluate the efficacy and safety and often 
effectiveness of new drugs.
Often dedicated to questions on how to best use 
treatments.
Gain marketing authorisation and patient access for a new product, 
extend labelling for an approved product.
Can focus on patient- centric endpoints, for example, 
response rate.
Provide data for submission to health technology assessment (HTA) 
bodies.
Establish proof of concept for combination trials or 
exploratory studies.
Designed with the requirements of regulatory agencies in mind. May seek to answer questions from the scientific 
community, regulators and/or payers for data that was not 
generated as part of the regulatory data provided under 
industry sponsored clinical trials.
Industry’s research portfolios are generally segmented to include 
research and early development trials (Phase I First in Human and 
Phase II), product development trials (Phase Ib- III) and medical 
affairs studies (both post first- indication as well as pre- first 
indication supportive of filing studies, proof of concept studies and 
evidence generation for access/reimbursement purposes), all of 
which may include academic cooperative group studies.
Academia’s research portfolios seek to increase 
knowledge and is centred on advancing patient care. 
Here, one can generally describe academic trials that 
are designed to learn followed by subsequent academic 
clinical trials designed to conclude.
See a marked need for Phase Ib trials (traditional Phase 1 trial 
is seen as a serial approach that adds time and cost to the 
development process).
Pragmatic clinical trials that test effectiveness of different 
therapy types in clinical practice.12
Need to meet regulatory requirements for regulators globally in 
order to achieve drug approval and generate data to facilitate 
HTA review and patient access. The European Medicines Agency 
and many HTAs, for instance, accept well- established efficacy 
endpoints, and consequently, many industry- sponsored clinical 
trials use progression- free survival as the primary endpoint.13
Can incorporate new endpoints (which are also a 
focus area of industry) to take advantage of advancing 
understanding of tumour biology, and these may include 
endpoints based on imaging, tumour kinetics, biological 
markers, quality of life and patient reported outcomes.
Concerned with the concept of sustainability, the ability to 
invest in research that will build new businesses that provide 
future revenue to sustain continued investment in research. 
Scientific advancement and satisfaction of unmet medical needs 
are required, but are not, on their own, sufficient to generate a 
sustainable research- driven business enterprise. An additional 
consideration for industry is the need to meet regulatory 
requirements for regulators globally in order to achieve drug 
approval and generate data to facilitate HTA review and patient 
access.
Decisions are made by volunteer members, are driven by 
the science, but also by the needs of the patients they 
see in daily practice. Investigators must be concerned 
with conducting research that is financially sustainable 
for themselves and the institutions they support, although 
they do not work primarily for profit.
their focus from Phase III to Phase I trials, rather they 
would like to more broadly see new models of collabo-
ration in Phase I through III trials. Immune- oncology 
networks and other models of research will arise here 
with no cooperative group involvement, due in part to 
this gap in the cooperative group collaboration model 
with industry.
Here, it is important to recognise that the manner in 
which clinical trial evidence is being utilised to support 
industry registration programme has changed over the 
last decade. Classic drug development paradigms have 
moved from sequential Phase I, II, III studies and are 
being replaced by faster to market regulatory approval 
strategies. Indeed, the clinical trial landscape is contin-
uously evolving, and recent advances such as those in 
omics- based capabilities, for example, are uncovering 
tremendous therapeutic opportunities.
EXAMPLES OF SUCCESSFUL COLLABORATIVE MODELS FOR 
ACADEMIA-INDUSTRY CLINICAL TRIALS
One might think, that complex infrastructure decreases 
agility during study set- up and conduct. However, in a 
forward- looking sense, an infrastructure which addresses 
and solves the bottlenecks, the trials you plug into it should 
benefit from that infrastructure, and, ultimately, bring 
agile clinical trial development. At the start, there can be 
long contractual negotiations, multiple additional guid-
ance/working documents and decision- making needs 
to be aligned across team members/governance bodies 
and across the different partners of the study. From an 
industry perspective, working with one cooperative group 
can be vastly different than working with another cooper-
ative group, because the internal rules of conduct differ 
significantly depending on the group, and even within a 
group depending on the type of collaboration model.
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Table 3 Examples of successful collaborative models for academia- industry clinical trials







Randomised studies in the HER2(+) 
setting
Established changes in the standard of care for patients with 
HER2+ breast cancer while answering important questions for 
the scientific community.14–23 Fast enrolment, valuable scientific 
input and medical expertise from both academia and industry. 
Benefitted from large network of sites and effective operational 




Basket trial conducted in patients 
with BRAF V600 mutation- positive 
cancers (solid tumours and multiple 
myeloma, except melanoma and 
papillary thyroid cancer).24
Assessed efficacy and safety of vemurafenib.
Efficacy was seen in some but not other histologies. Regulatory 
approval for small biomarker defined populations can be 
achieved through this type of ‘basket’ trials
STAMPEDE 
(NCT00268476)
Umbrella trial assessed the effect 
of adding different agents to the 
standard of care for men starting 
long- term hormone therapy for 
metastatic or high- risk non- 
metastatic prostate cancer.25
Single histology, multiple biomarkers were each matched to 
treatments. Assessed effects of zoledronic acid, docetaxel 
or both (zoledronic acid showed no evidence of survival 
improvement; docetaxel chemotherapy, given at the time of long- 
term hormone therapy initiation, showed evidence of improved 
survival accompanied by an increase in adverse events).26 
Trial was later amended to include assessment of abiraterone 
and enzalutamide, either alone or in combination, as well as 
radiotherapy for patients with newly- diagnosed metastatic 
disease.
EORTC trial 1559 
(NCT03088059)
Phase II pilot study of personalised 
biomarker- based treatment strategy 
or immunotherapy in patients with 
recurrent/metastatic squamous cell 
carcinoma of the head and neck.
Based on potential biomarkers and molecular alterations 
identified in the biopsy from the central platform, patients 
were allocated to biomarker- positive patient cohorts and 
immunotherapy cohorts. Very efficient setup in practice, an 
almost disease specific infrastructure within an infrastructure, 
somewhat transparent to the investigator in the field. The 
network infrastructure is powerful, and the data can be used for 
further learning. Enabled study on patient population with an 
unmet medical need.
Cumbersome clinical trial operational systems can 
substantially hinder and add to the cost of drug devel-
opment.2 Thus, efforts should be directed towards 
re- engineering and simplifying current processes for 
trial pre- activation, activation and conduct, and, where 
possible, using central infrastructure and eliminating 
overlapping administrative and logistical requirements. 
Examples of successful collaborative models for academia- 
industry clinical trials are presented in table 3.
One would imagine, that this is a similar experi-
ence for cooperative groups working with a variety of 
industry partners; some of the complexity is rooted in 
not knowing enough about how to work with the other 
entity and still come out with what you need for your 
trial or membership/independence. Partners need to 
learn and understand their roles during study set- up and 
conduct, understand what is, and what is not, negotiable, 
for example, what are industry’s needs for compliance 
with internal processes and regulatory requirements and 
what does academia need from a compliance/principles 
perspective. Finally, given the complex infrastructure, 
there needs to be stable team membership to ensure 
study- specific knowledge and experience are retained 
and maintained and strengthened over the course of the 
study.
Industry feels that an area of potential improvement 
in collaboration within umbrella networks of coop-
erative groups would be to shift the discussion from 
a clinical trial- based approach to a disease area- based 
approach, aligning the model needs with the end use 
intended for the study data. Industry is very much ‘reac-
tive’ to the investigator sponsored trial submission but 
would be open to larger discussions regarding develop-
ment of drugs across a tumour type in different models 
aligned with the intended use of the study data. A chal-
lenge to such an approach is that different companies 
will not share their Clinical Development Plans with 
one another for competitive reasons, and perhaps 
combined with the knowledge that each academic 
group may submit its concept to one or more compa-
nies for support.
CURRENT CHALLENGES FOR ACADEMIA-INDUSTRY CLINICAL 
TRIALS IN EUROPE
The European Union (EU) Clinical Trials Regulation 
(EU CTR) was adopted by the Council of the European 
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Union and the European Parliament, applicable to all 
interventional trials, and published in the Official Journal 
of the European Union on 27 May 2014.3 It repeals Direc-
tive 2001/20/EC, which resulted in loss of competitive-
ness for European trialists and a reduction in trials of up 
to 25% since 2007 due to, among other reasons, an excess 
of bureaucratic requirements which were especially chal-
lenging for non- commercial cancer clinical trials.1 4
The EU CTR will go into effect when the new EU Clin-
ical Trials Portal is completed by EMA. In the meantime, 
sponsors must comply with the EU Clinical Trials Direc-
tive (EU CTD) as implemented into national laws.
While implementing the EU CTD, several member 
states’ national legislations made a distinction between 
commercial and non- commercial research and/or spon-
sors. This measure has helped a proportion of academic 
research to survive, but it also introduced a barrier that 
hinders private public partnerships.
From an industry perspective, the main challenge may 
arise in cases where these two types of trials produce results 
that the industry supporter decides, post facto, to use as a 
part of a commercial regulatory filing. Given the propen-
sity of small, large and umbrella networks of cooperative 
groups to submit large Phase III studies to industry for 
supported studies, careful consideration must be applied 
by all parties involved regarding how countries and their 
sites interpret current legal framework.
With the upcoming implementation of the EU CTR, it 
is not yet known to which extent these elements of the 
national legislations will remain and still apply beyond 
the implementation of EU CTR.
Interpretation of the EU Clinical Trials Directive
The specific issue of most critical concern arises when a 
particular country’s health authority interprets the EU 
CTD as to ensure that clinical trial data cannot be shared 
with industry from a study that was initially submitted as 
a non- commercial trial to the relevant national health 
authorities. This issue is compounded, when other EU 
countries’ health authorities involved in the study inter-
pret the EU CTD in a way that allows the clinical trial 
data to be shared with industry from a study that began as 
a non- commercial study. For a large multinational Euro-
pean academic cooperative group trial that involves sites 
from both of these types of countries in their studies, the 
impact is clear. Providing industry with the clinical trial 
data for only a percentage of the patients enrolled into 
the trial may cause industry to find this model of collab-
oration less attractive, particularly when the investment 
provides a positive clinical trial result for a Phase III study 
that cannot be used as part of a regulatory submission.
The impact on academic- clinical trials for some of these 
large academic multinational cooperative groups is, that 
their wishes to conduct large Phase III trials add a layer of 
complexity and risk to a company’s decision on whether 
to collaborate on a large Phase III trial with the group in a 
supported study setting. Given the external market forces 
compelling companies to generate data quickly with fast 
and efficient drug development, the practical impact may 
be a chilling effect on choosing a model of collaboration 
where the academic cooperative group cannot guarantee 
provision of data from all sites that wish to participate in a 
large Phase III study in a timely manner due to the dispa-
rate interpretations of the EU CTD within Europe.
However, industry- academia clinical trials still do move 
forward. From an industry perspective, the contract with 
the lead academic group for a clinical trial generally 
requests, that in the event that a clinical trial is positive 
and the company would like to use the data for a regu-
latory filing, the lead academic cooperative group must 
provide this data to industry. In many cases, there would 
then be a subsequent lump sum payment by industry to 
pay for the database, database cleaning and transfer to 
industry to meet the regulatory agencies requirements.
From the academic cooperative groups’ perspective, 
the variable understanding of Ethics Committees (ECs), 
which are less touched by the EU CTD, also needs to be 
addressed, since this is an area of considerable risk and 
requires dialogue for clarity. For a commercial trial, the 
cost of standard of care, drug and other study- related 
activities are commonly covered by the commercial 
sponsor. This results in a higher per- patient cost, but the 
data can be used for commercial purposes.
A proposed novel solution would be for a third submis-
sion for non- commercial trial that has the potential to 
be used for commercial purposes in the correct circum-
stances, and agreeing in advance about what needs to be 
in place with ECs and regulators, for example, informed 
consent form (ICF) language, guarantees for money to be 
paid if the study is to be used in a filing, etc, in the event 
the non- commercial trial’s data be used for commer-
cial purposes. Lacking an additional model, there is the 
potential for a chilling effect for some EU countries that 
cannot offer assurances on the ability for industry to use 
the data for commercial purposes for a Phase III academic 
cooperative group trial.
A best practice proposal would be to segment, in 
advance, those countries that interpret clinical trial 
legislation to not allow sharing of data with industry for 
non- commercial trials to ensure that the considerations 
written above have been adequately described to them.
Finally, there is a lack of guidance concerning the 
implementation of the General Data Protection Regula-
tion (GDPR), which creates difficulties for international 
collaborations in clinical research.5 6 GDPR must be 
viewed in light of the upcoming EU CTR, in vitro diag-
nostic regulations and medical devices regulations. The 
impact of these regulations on academic clinical research 
in Europe is still to be determined and should be 
discussed in greater depth between CAREFOR, industry 
and stakeholders interested in improving the opportuni-
ties for academic clinical research in Europe.
Commercial versus non-commercial intent
In investigator initiated trials (IITs), the regulatory 
sponsor is generally an investigator or an academic group, 
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whereas a pharmaceutical/biotechnology/medical device 
company is generally the sponsor of an industry clinical 
trial. While academic clinical trials are often considered 
to only encompass the former IITs, both models are used 
in collaboration with academic cooperative groups and 
have sought to answer key scientific questions from the 
oncology community.7
In general, a clinical trial is considered to have commer-
cial intent when sponsored by a pharmaceutical manu-
facturer, has registration as intent and registration as an 
intent is included in the competent authority (CA) and 
EC submission for trial approval and in the ICF. Trials with 
non- commercial intent do not have registration as intent, 
so registration as an intent is not included in the ICF. 
However, these definitions have become blurred, because 
it is difficult to judge the intent of academic studies 
submitted with non- commercial intent which have gone 
on to provide data that substantially improves patient 
treatment outcomes and care. In these cases, pharmaceu-
tical companies may want to have the ability to retrospec-
tively file the data if allowed by regulators (CA) and ECs 
for the benefit of granting the widest access possible (ie, 
product labelling for an indication) to the new treatment 
for the benefit of patients with cancer.
Today, human biological materials (HBMs) and images 
are routinely collected during cancer clinical trials, and 
this component of the study is included in the ICF. Turning 
a trial to commercial intent means that the sponsor 
transparently informs the ECs of this use of the material 
and/or images. It is important to note the concept of a 
one- time consent in Article 28 (2) of the EU CTR, that 
allows data to be used beyond the end of a clinical trial 
for research purposes. The concept, now enshrined in 
EU law, will give patients the option, while enrolling for 
a clinical trial, to donate their data for research purposes 
beyond the end of a clinical trial (protected with strict 
ethical safeguards), bolstering research protection on 
clinical trial data.
COMMON LEGAL NEGOTIATION POINTS IN CONTRACTS FOR 
CLINICAL STUDIES
Given the different types of academic cooperative groups, 
clinical trials, as well as the variable models, regulations 
and complexities noted in this article to this point, there 
is a necessity for a clear contract between industry and 
academia to set the basis for the collaboration.
First, the contract should fully clarify the perspectives of 
each of the parties and ensure both parties have the same 
vision of their collaboration (ie, contract research organ-
isation or equal partnership, the metrics to consider for 
evaluating the research).
Second, it should harmonise the different administra-
tive/operational procedures and legal requirements of 
the parties, including timelines, costs and intellectual 
property (IP) rights. This part of contract negotiation can 
take a considerable amount of time, so it is advised that 
legal teams are involved early in the negotiations.
Finally, the advantages of the collaboration must be 
clearly set so as to demonstrate the positive aspects of the 
collaboration.
Mutual scientific interest is the driver for partner-
ship, and operational requirements and contract defini-
tions can play an important role in developing a sound 
contract. There are a number of points to consider when 
setting up a working agreement:
 ► Given the nature of academic groups, membership 
agreements and a master contract with each member 
site should be in place before the start of each study. 
Here, it should be permissible to share the site list.
 ► The intended use of the data and the timing of its use 
by industry should be clearly agreed to in the initial 
agreement.
 ► IP rights granted to industry include, at a minimum, 
‘Freedom to Operate’ (FTO) with industry’s Study 
Drug/Agent in the contract. FTO is the ability to 
perform a particular commercial activity (eg, commer-
cialise a product, provide a service, perform a manufac-
turing process or use a product) without ‘infringing’ 
on the academic cooperative group, research sites or 
third party’s valid IP rights. The rights in the contract 
to conduct the academic study with support and drug 
from industry should allow industry to have FTO for 
its Study Drug/Agent.
 ► There should be bi- directional points of contact and 
escalation for operational, financial and competitive 
considerations.
 ► The database structure and technical standardisation 
and licensing electronic data capture systems should 
be included.
 ► IP, inventions, data ownership/use rights, biomarker 
invention rights, confidentiality rights, etc, need to be 
agreed.
 ► The retrospective or prospective acquisition of data-
base should be discussed and agreed in advance.
 ► Indemnity language needs to be included.
 ► Publication rights including a publication policy 
needs to be written and agreed to prior to the start of 
the study.
 ► It is also important to note, that the overall budget 
and budget rate cards should differ depending on 
type of trial.
 ► Access to the database during and after the conduct 
of the study should be clearly negotiated within the 
contract.
 ► Safety data reporting and quality agreements should 
be included within the contract (or as an addendum).
Budgeting and fair market value
Conducting an advanced international IIT in a fully 
developed professional environment and providing 
data readily acceptable by regulatory agencies globally 
compared with running a local study intended for publi-
cation only do not bear the same features and costs, but 
both types of trials can be run by academic cooperative 
groups as ‘academic trials’.
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Academic Cooperative Groups indicate, that industry 
often applies the same fair market value (FMV) refer-
ence to both scenarios, for which bench marking is not 
clear to academia, nor is it disclosed to them. Further, 
industry is not inclined to provide funds to a group or 
investigator beyond FMV, since this could be viewed as 
a ‘kick- back’ by law enforcement.8 Since some academic 
cooperative groups have sites in countries with different 
costs, providing a set cost across the board can create the 
perception that the drug company is inducing doctors to 
enrol patients in the trial by paying more than FMV for 
the test in that country. Industry needs to avoid even the 
smallest perception of impropriety at all costs, particularly 
when involving the provision of monetary or like- kind 
compensation to investigators, who also may prescribe 
their drugs. As a result, industry scrutinises the budgets 
to ensure they are FMV as a whole, but also in the loco- 
regional sense.
Delays are an oft- mentioned concern, and they might 
arise, for example, because of time contracting and 
reviewing study designs and budgets through interna-
tional hierarchies or due to slow activation of the clin-
ical trial. Therefore, a proposal for decreasing delays in 
start- up of clinical trials would be to create an interme-
diary focussed on improving operational capabilities, 
forming recommendations for database standards, data 
access alignment, contract terms and reviewing FMV for 
different study types should be considered. This interme-
diary would ideally comprise operational, legal, financial 
and medical individuals with both academic and industry 
experience in both academic and industry sponsored 
trials.
DATA ACCESS AND MANAGEMENT MODELS TO GOVERN THE 
FLOW OF INFORMATION AND DATA BETWEEN ACADEMIA AND 
INDUSTRY
Given the changes in classic drug development that are 
becoming increasingly evident, and these reflect, in 
part, the desire for new drugs to come to market for the 
benefit of cancer patients sooner, models that enable 
research to be conducted in pan- European collaboration 
with academia should consider addressing changes in 
how data is being utilised and the market forces at work, 
which may favour one model over another, in an effort to 
create fast and efficient drug development for the benefit 
of patients with cancer.
To begin, however, the clear distinction between data 
ownership and data access must be made. From an 
academic cooperative group perspective, nobody can own 
individual patient’s data, but one can own the database. 
From an industry perspective, in standard IIT contract 
language, the cooperative group owns the data under 
an IIT, and this is achieved through its agreements with 
its cooperative group member institutions. So, for the 
purpose of this article, we speak about being the primary 
custodian of the data. The creator of the data is the custo-
dian, and as the custodian, they have the responsibility 
of seeing how it is shared and used, notably what rights 
can be granted to the data to third parties who supported 
the conduct of the study with both drug and funding. 
From the IIT sponsor’s perspective, there are duties asso-
ciated with being the custodian of the data, and the focus 
should be placed on the responsibilities associated with 
custodianship and on ensuring data access. From indus-
try’s perspective, support of trials is premised on the 
agreement of the IIT sponsor with sharing the data with 
industry in a particular format before the start of the trial 
(which can be as broad as sharing the publication of the 
trial results, or as focussed as sharing the raw clinical trial 
database and analyses databases).
The differences between HBM and data need to be 
recognised, apparent and described in the contract. HBM 
are a finite resource, whereas data is an infinite resource.
Academic cooperative groups acknowledge that there 
are circumstances, where the design of the study allows 
for an earlier look at the data (eg, interim analyses) 
without impacting the integrity of the primary endpoint. 
Earlier transfers of data can be requested and paid for 
if agreeable to both parties. The key, of course, is to not 
impact the integrity of the trial.
It should also be noted, that as soon as trial results are 
made public, industry, in the interest of patient safety and 
providing accurate replies to the doctors and healthcare 
providers worldwide, appreciates receiving the data at the 
earliest possible time point after the primary endpoint 
to (a) understand the data, (b) provide relevant updates 
to healthcare providers and (c) provide legally required 
information to investor relations per US Securities and 
Exchange Commission and other guidelines.
The data generated by academia can either serve regis-
tration purposes or be used for internal research by 
industry and the academic cooperative group. Depending 
on the aim of the data use, the conditions of access to 
the data can potentially change and the collaboration 
between industry and academia can differ.
The time point at which data can be shared must also 
be agreed. Academia stipulates that this be after comple-
tion of statistical analysis of the primary endpoint. Safety 
data can be shared earlier, as long as it does not interfere 
with the integrity of the analysis of the primary endpoint.
Retro- acquisition of the database from academia to 
industry is another consideration. Industry sometimes 
seeks to acquire the database of an academic study, and 
the conditions of this retro- acquisition of databases, and 
the potential consequences on the status of the academic 
study, need to be addressed.
Access to data by industry cannot always be included in 
the main research contract. Indeed, in many countries, 
granting industry access to data in the main contract 
prevents the recognition of academic research status. 
Consequently, academia and industry have usually relied 
on regulating this interaction post hoc following comple-
tion of a study, or, alternatively, have aimed to develop 
contract amendments. These amendments, however, 
bring additional difficulties in terms of administrative 
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burden and cost estimation. To be clear, the models of 
data acquisition are mapped to respect principles of inde-
pendence as well as regulatory requirements. Whether 
the research is commercial or non- commercial must be 
declared, so changing status is possible, but the partners 
must abide by some rules. Moving forward, a best prac-
tice proposal would be to clarify, upfront, what these 
suggested rules may look like for the different types of 
clinical trials.
Right to use data for all legal purposes versus non-
commercial purposes
For industry, the right to post hoc use of data needs to 
be clear. One also needs to consider that if not done 
fully when the trials are conducted, overall Good Clinical 
Practice compliance is hard to achieve retrospectively, if 
the trail data and information are to be used for regula-
tory approval purposes. So, having clarity on this upfront 
during contact discussions is very important.
For filing, industry requires a timeline and needs to 
make sure that the expectations are aligned at the start 
of the trial. This needs to be put into the terms of the 
contract. The cost of data cleaning, regulatory body costs, 
etc required for filing, and the previous experience of the 
academic group are important. As such, there is a need 
for the industry biometrics and monitoring teams to meet 
with academic teams. Currently, this type of meeting 
between industry and academic cooperative group 
biometrics and monitoring teams is underutilised in the 
eyes of industry, and there is room for improvement.
There are different models of data sharing, and a recent 
example is an agreement signed between GlaxoSmith-
Kline and the EORTC for the transfer of HBM and clin-
ical data collected as part of cancer immunotherapeutic 
research. Under the agreement, GlaxoSmithKline has 
provided EORTC access to all data and samples of the 
MAGRIT and DERMA negative studies, and these data 
comprise a tremendous source of research for academia.9
In their Requirements for Trials Between Academic 
Groups and industry, ENGOT proposes options for 
organising the clinical trial database.10 Under Option 
A, the database resides with the lead academic group. 
There is quality assurance and certified database soft-
ware, audits by industry or industry assigned auditors 
and transfer of database to industry for registration issues 
and analysis. Under Option B, the lead academic group 
and industry agree on the choice of a CRO, the CRO is 
contracted by the lead academic group, and the data-
base is located at the CRO. There is quality assurance 
and certified database software, audits by industry and by 
the lead academic group, if deemed necessary, installa-
tion of standard operating procedures for the respective 
protocol and information system for any violation to the 
sponsor, and transfer of the complete database to the lead 
academic group for scientific analysis and to industry for 
registration purposes. Finally, under Option C, the lead 
academic group and industry agree on the choice of a 
CRO, but here the CRO is contracted by industry, and 
every transfer of the database for analysis must be granted 
by the leading academic group.
In some cases, especially in the case where there is 
registration potential, it is easier for umbrella cooperative 
groups to use CROs, since there is a great deal of vari-
ability in the ability of each member cooperative group in 
terms of data management, monitoring and drug safety 
reporting in each country.
EORTC holds that the integrity of the database be 
controlled by an independent group with a focus on the 
validity of the primary endpoint release, the statistical 
analysis and publication be independently processed and 
charters are drawn for the use of HBM. However, if the 
CRO holding the database is contracted for by industry, 
this would not meet EORTC’s criteria for an academic 
study despite whether or not the actual transfer of the 
database to pharma must be granted by the lead academic 
group. This viewpoint difference between ENGOT 
and EORTC creates a heterogenous environment for 
academic research in Europe. Industry believes that vari-
ations on the EORTC model are possible and exist today 
(eg, cooperative groups participating in pharmaceutical 
company sponsored trials where a CRO or the pharma-
ceutical company holds the database), and it is critical for 
advancement of the science for each party to be as collab-
orative as possible to move the field forward when there is 
a mutual scientific interest to pursue a clinical trial.
EMERGENCE OF NEW COLLABORATIVE MODELS
In the last 5 to 7 years, there has been an emergence of 
new collaborative models which could potentially accel-
erate academic research. These models are reacting 
to a complex clinical trial landscape, where the under-
standing of disease and treatment paradigms are evolving 
and changing at a faster pace in areas like immuno- 
oncology. There is a need to develop successful collabo-
rations, including a sharing of data across networks, and 
these models are expanding on the self- imposed limits of 
previous models of collaboration in the interest of coming 
to answers more quickly and efficiently for patients with 
cancer. In addition to accelerating the generation and 
sharing of research data, there is also a high interest in 
new types of Real World Data sharing platforms. Table 4 
presents examples of these new and emerging models 
outside of the current academic cooperative group 
networks.
CONCLUSION
This paper is a call to action to all communities in academia 
and industry that there is a need to examine, discuss and 
either clarify or improve on the way academia- industry 
research is being conducted. There are several drivers for 
change in academia- industry collaboration: collaboration 
and exchange of knowledge, streamlined contracting and 
agreements, bidirectional exchange of knowledge and 
exchange of samples and technology. The value of the 
collaboration can be maximised by focussing on strengths 
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Table 4 Presents examples of these new and emerging models outside of the current academic cooperative group networks
Collaborative model Description
Innovative Medicines Initiative, 
a partnership between the 
European Commission and 
European Federation of 
Pharmaceutical Industry 
that connects academic 
and pharmaceutical industry 
research.
Projects cover components of the different steps of medicines development in several disease 
areas, and in cancer include BD4BO, CANCER- ID, EBiSC, HARMONY, ITCC- P4 ITCC, 
MARCAR, Onco Track, PIONEER, PREDECT, and Quic- Concept(27).
BMS II- ON (International 
Immuno- Oncology Network)
International peer to peer collaboration (230 investigators, 13 different sites) to advance 
I- O science and translational medicine. Results thus far include Genetic Basis for PD- L1 
Expression in Squamous Cell Carcinomas of the Cervix and Vulva28, Intratumoral Balance 
between Metabolic and Immunologic Gene Expression Is Associated with Anti- PD-1 Response 
in Patients with Renal Cell Carcinoma29, Intestinal microbiome analyses identify melanoma 
patients at risk for checkpoint- blockade- induced colitis30, Combination Therapy with Anti- 
PD-1, Anti- TIM-3, and Focal Radiation Results in Regression of Murine Gliomas31, Interferon- 
Production by Peripheral Lymphocytes Predicts Survival of Tumor- Bearing Mice Receiving Dual 
PD-1/CTLA-4 Blockade32.
Roche imCORE 
(immunotherapy centres of 
research excellence)
Clinical research partnership comprising global network of basic and clinical scientists from 26 
academic research institutions in cancer immunotherapy working with scientists from Roche 
and Genentech. Master agreements with the member sites, data sharing policies, central 
laboratory options for standardised biomarker research, etc have been implemented. Roche 
is working as one of the research institutions in collaboration with the network on existing and 
new investigational medicines, diagnostic technologies and emerging data. The network aims 
to identify and prioritise the most promising new treatment approaches.
Lung MAP (SWOG S1400, 
NCT02154490)
Collaboration across academia with multiple industry partners and advocacy groups in the 
United States. Multi- drug, multi- substudy, biomarker- driven squamous cell lung cancer clinical 
trial employing genomic profiling to match patients to substudies testing investigational 
treatments that may target the genomic alterations, or mutations, found to be driving the 
growth of their cancer33. Patients are tested just once at enrolment according to a ‘master 
protocol’ and assigned to one of multiple trial substudies, each testing a different drug from 
a different pharmaceutical or biotechnology company. There is a shared information and 
infrastructure, better access for patients to promising drugs, better access for researchers 
to relevant enrollees based on genomic profiles, and less time and money needed before 
investigational drugs can be tested. A variety of pharmaceutical and biotechnology companies 
can participate in Lung MAP, each of which can test their treatment in a Lung MAP substudy.
IQNPath (International Quality 
Network for Pathology)
A harmonisation project serving as an example of how academia can partner to address 
scientific and clinical application questions in oncology. IQNPath is a multi- stakeholder 
forum for improving quality in tissue- based biomarker assessment, enables the exchange of 
expertise, coordination of interactions and sharing of benefits by developing value through joint 
workshops, trainings, tools and data resources, and it promotes external quality assessment/ 
proficiency testing.
EORTC SPECTA A pan- European screening programme to reach patients outside of clinical trials. It has a 
protocol for longitudinal collection of cancer patient data and human biological materials 
without immediate interventional intent, and it collects informed consent which allows future 
unspecified use of the collected data and human biological materials, provided that all 
undefined testing eventually obtains ethical committee approval (without repeat consent).
and mutual areas of interest, crafting a collaboration 
model and contract that is fit for the given purpose and 
focussing on programmes that provide meaningful scien-
tific patient- centric advances that go beyond only compet-
itive considerations.
Industry- wide analysis shows greater pressures for 
industry to move more quickly from first in man to 
patient access coupled with fast and efficient early devel-
opment. This is the state of affairs for industry at a time 
when in areas like cancer immunotherapy more than 
1000 different combinations were being tested in clinical 
trials in 2018. One impact of these external pressures is 
that industry and academia have evolved different types 
of collaboration models that were in place just 5 years ago.
From the perspective of industry, there are ways to 
create successful partnerships with academia. Specifically, 
there need to be:
 ► Dedicated responsibilities to act as liaisons at a port-
folio level.
 ► Meetings need to be structured as opposed to ad hoc.
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Box 1 Principles of interactions between the academia and 
industry
1. Clarify the roles and responsibilities of all partners involved in the 
study to generate a strong sense of belonging to a team.
2. Involve legal teams from an early stage, in order to draft a contract 
with a clear vision of the study reflecting the needs of both parties.
3. Acknowledge that data is an important output of the study and the 
creator of the data is its custodian bearing the responsibility con-
cerning sharing it in the ultimate interest of the patient.
4. Agree on the intent of the trial prior to its start. If trial results indi-
cate a societal/patient benefit bringing the study to registration, an 
agreement needs to be envisaged that meets both the requirements 
of industry and academic cooperative groups noting that some is-
sues (eg, ICF language) may not be able to be obtained from 100% 
of the patients retrospectively, while other contract areas (eg, cost of 
data transfer) may be negotiated in later agreements subject to fair 
market value and other applicable regulations.
 ► Communication and vision need to be transparent 
and at least partially shared, for instance, not every 
successful collaboration needs to have three to four 
ongoing clinical trials. Some groups prefer one large 
trial which can take up to 18 months for study set- 
up, while other groups envisage a larger number of 
collaborations.
Moving forward, industry and academia need to work 
smarter together, new options of collaboration need to 
be discussed and established models need to be revisited.
Items introduced in this paper should continue to 
be discussed as separate matters (eg, GDPR, EU CTR, 
Models of Collaboration, Common Points of Contract 
Language Negotiation) and elaborated in separate arti-
cles in an effort to clarify understandings and improve 
the direction for academic clinical trials in the field of 
oncology in an era of fast paced global changes in clinical 
research environments.
Lastly, we propose principles of interaction (box 1) 
between the academia and industry which may provide 
guidance towards creating a clear and successful collabo-
ration between both parties with the underlying premise 
that all clinical trials performed capture data of sufficient 
quality. Patients with cancer, who we serve, are counting 
on it.
Acknowledgements Editorial support was provided by John Bean PhD, Bean 
Medical Writing, Halle, Belgium. Final approval of the manuscript rests solely with 
the authors.
Collaborators CAREFOR members representing industry: AstraZeneca: Nathalie 
Varoqueaux; Boehringer- Ingelheim: Claas Frohn; Bristol- Myers Squibb: Patricia 
Cornet; F. Hoffmann- La Roche Ltd.: Thomas Buechele; Genentech, Inc., A Member 
of the Roche Group: Arthur Cannon; Ipsen: Jose Amauri Soares; Eli Lilly and 
Company: Nora Drove Ubreva; Novartis: Michael Zaiac; Sanofi: Marika Crohns.
Funding This work was supported by the European Society for Medical Oncology 
(no grant number applicable).
Competing interests RAS reports: In the past two years, I have received honoraria 
as a consultant at advisory boards from Abbvie, Astra Zeneca, MSD, Pfizer, 
Regeneron, Roche and Takeda. In the past two years, I have received honoraria 
as a speaker from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD and Roche. 
DMC in the last two years: Genentech/Roche and Takeda Financial Support of ETOP 
trials (president and scientific chair): AstraZeneca, BMS, Boehringer Ingelheim, 
Genentech, MSD, Roche and Pfizer; FC reports personal fees from Amgen, 
personal fees from Astellas/Medivation, personal fees from AstraZeneca, personal 
fees from Celgene, personal fees from Daiichi- Sankyo, personal fees from Eisai, 
personal fees from GE Oncology, personal fees from Genentech, personal fees from 
GlaxoSmithKline, personal fees from Macrogenics, personal fees from Medscape, 
personal fees from Merck- Sharp, personal fees from Merus BV, personal fees from 
Mylan, personal fees from Mundipharma, personal fees from Novartis, personal fees 
from Pfizer, personal fees from Pierre- Fabre, personal fees from prIME Oncology, 
personal fees from Roche, personal fees from Sanofi, personal fees from Seattle 
Genetics, personal fees from Teva, outside the submitted work; PGC reports 
personal fees from Bayer, personal fees from Deciphera, personal fees from Eisai, 
personal fees from Eli Lilly, personal fees from Nektar Ther, personal fees from 
Pfizer, grants from Advenchen Lab, grants from Amgen Dompé, grants from AROG, 
grants from Bayer, grants from Bluerint, grants from Daiichi Sankyo, grants from 
Deciphera, grants from Eisai, grants from Eli Lilly, grants from Epizyme, grants from 
Glaxo, grants from Karyopharm, grants from Novartis, grants from Pfizer, grants 
from PharmaMar, outside the submitted work; RM reports personal fees from Pfizer, 
outside the submitted work; AH reports grants and non- financial support from 
Abbott Molecular Inc, grants from Amgen (Europe) GmbH, grants and non- financial 
support from Amgen Inc, grants and non- financial support from Amgen Ltd, grants 
and non- financial support from AstraZeneca AG Switzerland, grants and non- 
financial support from AstraZeneca UK Ltd, grants from AstraZeneca Wilmington, 
grants and non- financial support from Biodesix Inc, grants and non- financial 
support from Boehringer Ingelheim RCV GmbH & Co. KG, grants from Boehringer 
Ingelheim (Schweiz) GmbH, grants from Bristol- Myers Squibb Company, grants and 
non- financial support from Bristol- Myers Squibb International Corporation, grants 
and non- financial support from Eli Lilly Export SA, grants from Eli Lilly Regional 
Operations GmbH, grants and non- financial support from F. Hoffmann- La Roche 
Ltd, grants and non- financial support from Genentech Inc, grants from Merck KGaA, 
grants and non- financial support from MSD MERCK SHARP & DOHME AG, grants 
from Pfizer Inc, grants from Pfizer Pharma GmbH, grants from Takeda, outside the 
submitted work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data sharing not applicable as no data sets 
generated and/or analysed for this study.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, any changes made are indicated, and the use is non- commercial. 
See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
REFERENCES
 1 Negrouk A, Lacombe D, Cardoso F, et al. Safeguarding the future 
of independent, academic clinical cancer research in Europe for the 
benefit of patients. ESMO Open 2017;2:e000187.
 2 Dilts DM, Cheng SK, Crites JS, et al. Phase III clinical trial 
development: a process of chutes and ladders. Clin. Cancer Res 
2010;16:5381–9.
 3 The European Parliament and the Council of the European Union. 
Regulation (EU) NO 536/2014 of the European Parliament and of 
the Council 16 April 2014 on clinical trials on medicinal products for 
human use, and repealing Directive 2001/20/EC, 2014.
 4 Salgado R, Moore H, Martens JWM, et al. Steps forward for cancer 
precision medicine. Nat Rev Drug Discov 2018;17:1-2.
 5 EUR- Lex. EUR- Lex - 32016R0679 - EN. Available: https:// eur- lex. 
europa. eu/ legal- content/ EN/ TXT/? uri= celex% 3A32016R0679
 6 Negrouk A, Lacombe D. Does GDPR harm or benefit 
research participants? an EORTC point of view. Lancet Oncol 
2018;19:1278–80.
 7 Lacombe D, Negrouk A, Bean J. International investigator- 
driven clinical trials: challenges and opportunities for US–Europe 
cooperation through the US cooperative group networks. Clin 
Investig 2011;1:493–500.
 8 Forte. What’s Fair about Fair Market Value in Research? Available: 
https:// forteresearch. com/ news/ whats- fair- about- fair- market- value- 
in- research/
 9 EORTC. GSK hands over large tumour sample collection in exciting 
new collaboration. Available: https://www. eortc. org/ blog/ 2018/ 10/ 
Open access
12 Stahel RA, et al. ESMO Open 2020;5:e000628. doi:10.1136/esmoopen-2019-000628
04/ gsk- hands- over- large- tumour- sample- collection- in- exciting- new- 
collaboration/
 10 du Bois A, Reuss A, Pujade- Lauraine E, et al. European Network of 
Gynaecological Oncological Trial Groups' Requirements for Trials 
Between Academic Groups and Industry Partners--First Update 
2015. Int J Gynecol Cancer 2015;25:1328–30.
 11 Drummond MF, Mason AR. European perspective on the costs and 
cost- effectiveness of cancer therapies. J Clin Oncol 2007;25:191–5.
 12 Burock S, Meunier F, Lacombe D. How can innovative forms of 
clinical research contribute to deliver affordable cancer care in an 
evolving health care environment? Eur J Cancer 2013;49:2777–83.
 13 Ruof J, Knoerzer D, Dünne A- A, et al. Analysis of endpoints used 
in marketing authorisations versus value assessments of oncology 
medicines in Germany. Health Policy 2014;118:242–54.
 14 Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment 
of HER2- positive early breast cancer patients: a meta- analysis of 
published randomized controlled trials. PLoS One 2011;6:e21030.
 15 Piccart- Gebhart MJ, Procter M, Leyland- Jones B, et al. Trastuzumab 
after adjuvant chemotherapy in HER2- positive breast cancer. N Engl 
J Med 2005;353:1659–72.
 16 Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant 
chemotherapy for operable HER2- positive breast cancer. N Engl J 
Med 2005;353:1673–84.
 17 Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients 
with axillary- node- positive breast cancer: results of the FNCLCC- 
PACS 04 trial. J Clin Oncol 2009;27:6129–34.
 18 Perez EA, Suman VJ, Davidson NE, et al. Sequential versus 
concurrent trastuzumab in adjuvant chemotherapy for breast cancer. 
J Clin Oncol 2011;29:4491–7.
 19 Joensuu H, Kellokumpu- Lehtinen P- L, Bono P, et al. Adjuvant 
docetaxel or vinorelbine with or without trastuzumab for breast 
cancer. N Engl J Med 2006;354:809–20.
 20 Slamon D, Eiermann W, Nannini R. Phase III randomized trial 
comparing doxorubicin and cyclophosphamide followed by 
docetaxel (AC→T) with doxorubicin and cyclophosphamide 
followed by docetaxel and trastuzumab (AC→TH) with docetaxel, 
carboplatin and trastuzumab (TCH) in Her2neu positive ea. 32nd 
Annual CTRC- AACR San Antonio Breast Cancer Symposium, 
2009.
 21 Pivot X, Semiglazov V, Chen S, et al. Subcutaneous injection of 
trastuzumab - analysis of administration time and injection site 
reactions. ESMO 2012;2012:LBA5.
 22 Cameron D, Piccart- Gebhart MJ, Gelber RD, et al. 11 years' follow- 
up of trastuzumab after adjuvant chemotherapy in HER2- positive 
early breast cancer: final analysis of the Herceptin adjuvant (HERA) 
trial. Lancet 2017;389:1195–205.
 23 von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant 
pertuzumab and trastuzumab in early HER2- positive breast cancer. N 
Engl J Med 2017;377:122–31.
 24 Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple 
Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 
2015;373:726–36.
 25 STAMPEDE. Available: http://www. stampedetrial. org/
 26 James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, 
zoledronic acid, or both to first- line long- term hormone therapy in 
prostate cancer (STAMPEDE): survival results from an adaptive, 
multiarm, multistage, platform randomised controlled trial. The 
Lancet 2016;387:1163–77.
 27 IMI Project Factsheets. Available: http://www. imi. europa. eu/ projects- 
results/ project- factsheets
 28 Howitt BE, Sun HH, Roemer MGM, et al. Genetic basis for PD- L1 
expression in squamous cell carcinomas of the cervix and vulva. 
JAMA Oncol 2016;2:518.
 29 Ascierto ML, McMiller TL, Berger AE, et al. The intratumoral balance 
between metabolic and immunologic gene expression is associated 
with anti- PD-1 response in patients with renal cell carcinoma. Cancer 
Immunol Res 2016;4:726–33.
 30 Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses 
identify melanoma patients at risk for checkpoint- blockade- induced 
colitis. Nat Commun 2016;7:10391.
 31 Kim JE, Patel MA, Mangraviti A, et al. Combination therapy with anti- 
PD-1, Anti- TIM-3, and focal radiation results in regression of murine 
gliomas. Clin Cancer Res 2017;23:124–36.
 32 McNamara MJ, Hilgart- Martiszus I, Barragan Echenique DM, et al. 
Interferon-γ Production by Peripheral Lymphocytes Predicts Survival 
of Tumor- Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade. 
Cancer Immunol Res 2016;4:650–7.
 33 Lung- MAP. Lung cancer master protocol|. Available: https://www. 
lung- map. org/ about- lung- map
